Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Union-BHB in Locally Advanced Rectal Cancer
NCT07239466Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 3-hydroxybutyrate in rectal cancer. Primary endpoint: Complete Response Rate at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
3-hydroxybutyrate
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07239466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239466.